A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
CRA announces vice president promotions
CRA is proud to announce the promotions of four new vice presidents: Andrea Asoni in the Antitrust & Competition Practice; Rachel Berk in the Risk,...